Opdualag

DRUG4 trials

Sponsors

Krystal Biotech, Inc., Australian & New Zealand Children's Haematology/Oncology Group, University Health Network, Toronto, Nationwide Children's Hospital

Conditions

CancerChildhood Brain TumorChildhood CancerChildhood Solid TumorCutaneous MelanomaDiffuse Intrinsic Pontine GliomaHigh Grade GliomaMelanoma Stage III

Phase 1

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

RecruitingNCT05970497

Krystal Biotech, Inc.Cancer, Cutaneous Melanoma, Melanoma Stage III +1

Start: 2023-10-31End: 2027-07-31Target: 240Updated: 2025-05-18

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

RecruitingNCT06208657

Australian & New Zealand Children's Haematology/Oncology GroupChildhood Brain Tumor, Childhood Cancer, Childhood Solid Tumor +2

Start: 2024-07-10End: 2035-12-01Target: 90Updated: 2026-01-28

Phase 2

Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma

RecruitingNCT06319196

University Health Network, TorontoCutaneous Melanoma, Melanoma Stage IV, Mucosal Melanoma

Start: 2026-08-27End: 2030-02-15Target: 54Updated: 2026-06-04

Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG

Not yet recruitingNCT07644312

Nationwide Children's HospitalDiffuse Intrinsic Pontine Glioma, High Grade Glioma, Replication Repair Deficient +2

Start: 2027-03-01End: 2038-03-01Target: 12Updated: 2026-06-12

Related Papers

Abstract A044: Immune profiling tools for adult and pediatric cancer: From whole genome and transcriptome sequencing to immunotherapy clinical trial design

Cancer Research2025-03-11

Abstract B015: Transcriptome-based assessment of immune infiltration for molecular selection of pediatric patients with solid tumors for combination immune checkpoint inhibitor therapy

Cancer Research2024-09-05

Abstract B066: Bridging patient reported outcomes and CTCAE to improve supportive care and trial design: The PROptimise initiative

Cancer Research2024-09-05